Skip to main content
. Author manuscript; available in PMC: 2018 Feb 3.
Published in final edited form as: ChemMedChem. 2017 Jan 18;12(3):250–256. doi: 10.1002/cmdc.201600538

Figure 5. Toxicity of FCBL in cell lines exhibiting apoptotic resistance and its activity in primary chronic lymphocytic leukemia (CLL) cells.

Figure 5

(a) Flow cytometry analysis of apoptosis of CBL-sensitive (U937) and CBL-resistant (K562) cells after 24-h incubation with F, CBL, the mixture of equivalent F and CBL, i.e., F+CBL, and FCBL, respectively. Lower left, A-FITC−/PI−, living cells; lower right, A−FITC+/PI−, apoptotic cells; upper right, A−FITC+/PI+, dead cells; upper left, A−FITC−/PI+, necrotic cells. Inserted numbers in the profiles indicate the percentage of cells present in that area. (b) Evaluation of HSA-FCBL nanodrug activity on red blood cells, peripheral blood mononuclear cells, and primary CLL cells. Mean values plotted, n > 5, error bars are SEM. Student’s two-tailed - t test was used to determine p values. ** indicate p value < 0.01.